TNF and graft versus host disease: Cell free therapies including the administration of EVs, in-vivo amplification of regulatory cells and targeting immune checkpoint signaling pathways such as the TNF-TNFR2 axis are among some new emerging approaches to selectively control the reaction and intensity of the immune response which potentially could lead to better control of GVHD.